“Nirmatrelvir/ritonavir as a posible treatment for Long-COVID ”

Ignacio Pérez Catalán, Adriana Gascon Buj, Sergio García Muñoz, Iris Gómez Alfaro, Celia Roig Martí, Miguel Torres García, Roberto Reig Valero, Raúl Ferrando Piqueres, Lidón Mateu Campos, Jose-Manuel Ramos, Jorge Usó Blasco
2023 · doi:10.22541/au.167468572.23346732/v1
preprint OA: closed
📄 Open PDF View at publisher

Abstract

It is estimated that about 10% of patients who have been infected with SARS-CoV-2 worldwide suffer from Long-Covid, about 65 million people [1]. Although we are beginning to know its pathophysiology, there is still no evidence on its treatment. We present the case of a patient with persistent prolonged symptoms who had an optimal response to nirmatrelvir/ritonavir 2 years after acute infection.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

crossref
last seen: 2026-06-12T06:26:28.928433+00:00
europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-07-10T06:41:27.906138+00:00